These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25957442)

  • 1. Colorectal cancer: to stack or sequence therapy?
    Azvolinsky A
    J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957442
    [No Abstract]   [Full Text] [Related]  

  • 2. [Progress of chemotherapy in colorectal cancer].
    Komatsu Y
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1771-6. PubMed ID: 18064761
    [No Abstract]   [Full Text] [Related]  

  • 3. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
    Dohn LH; Jensen BV; Larsen FO
    Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495
    [No Abstract]   [Full Text] [Related]  

  • 4. Always look at the bright side of drugs?
    Nygren P
    Acta Oncol; 2015 Feb; 54(2):145-7. PubMed ID: 25608927
    [No Abstract]   [Full Text] [Related]  

  • 5. Multiagent regimens for metastatic colorectal cancer: if some is good, more must be better.
    Allegra C; George T; Yothers G
    J Natl Cancer Inst; 2011 Jan; 103(1):4-5. PubMed ID: 21123834
    [No Abstract]   [Full Text] [Related]  

  • 6. N9741: a phase III study comparing irinotecan to oxaliplatin-containing regimens in advanced colorectal cancer.
    Goldberg RM
    Clin Colorectal Cancer; 2002 Aug; 2(2):81. PubMed ID: 12453321
    [No Abstract]   [Full Text] [Related]  

  • 7. Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX.
    Chang DZ; Abbruzzese JL
    Clin Adv Hematol Oncol; 2005 May; 3(5):400-4. PubMed ID: 16167013
    [No Abstract]   [Full Text] [Related]  

  • 8. Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer.
    Garant A; Des Groseilliers S; Martin L; Ferland É; Vuong T
    Clin Oncol (R Coll Radiol); 2011 Sep; 23(7):497-8. PubMed ID: 21576010
    [No Abstract]   [Full Text] [Related]  

  • 9. Perforating dermatosis in a patient receiving bevacizumab.
    Vano-Galvan S; Moreno C; Medina J; Pérez-García B; García-López JL; Jaén P
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):972-4. PubMed ID: 19470057
    [No Abstract]   [Full Text] [Related]  

  • 10. Evolution of systemic therapy for metastatic colorectal cancer.
    Geh JI; Ma YT
    Colorectal Dis; 2011 Aug; 13(8):852-4. PubMed ID: 21762349
    [No Abstract]   [Full Text] [Related]  

  • 11. Turning point for colorectal cancer clinical trials.
    Meropol NJ
    J Clin Oncol; 2006 Jul; 24(21):3322-4. PubMed ID: 16849744
    [No Abstract]   [Full Text] [Related]  

  • 12. Oxaliplatin combinations as first-line therapy in advanced colorectal cancer.
    Clin Colorectal Cancer; 2002 Aug; 2(2):78-80. PubMed ID: 12453320
    [No Abstract]   [Full Text] [Related]  

  • 13. [5-fluorouracil and leucovorin therapy for advanced colorectal cancer].
    Shimoyama S; Kondo K; Kataoka M
    Nihon Rinsho; 2003 Sep; 61 Suppl 7():356-9. PubMed ID: 14574912
    [No Abstract]   [Full Text] [Related]  

  • 14. First description of an uterine perforation potentially imputable to treatment with bevacizumab.
    Uguen T; Leconte B; Desgrippes R; Tchoundeu B; Bretagne JF; Manfredi S
    Acta Oncol; 2012 Nov; 51(8):1102-4. PubMed ID: 23020310
    [No Abstract]   [Full Text] [Related]  

  • 15. Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens.
    Saam J; Critchfield GC; Hamilton SA; Roa BB; Wenstrup RJ; Kaldate RR
    Clin Colorectal Cancer; 2011 Sep; 10(3):203-6. PubMed ID: 21855044
    [No Abstract]   [Full Text] [Related]  

  • 16. [Chemotherapy for elderly patients with colorectal cancer].
    Kuboki Y; Mizunuma N
    Gan To Kagaku Ryoho; 2007 Mar; 34(3):380-6. PubMed ID: 17353628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Advances in the treatment of metastatic colorectal cancer with bevacizumab].
    Longo F; Mansueto G
    Tumori; 2006; 92(5):suppl 1-12. PubMed ID: 17168449
    [No Abstract]   [Full Text] [Related]  

  • 18. Maintenance therapy for colorectal cancer.
    Marshall JL
    Oncology (Williston Park); 2014 Apr; 28(4):322, 324. PubMed ID: 24839806
    [No Abstract]   [Full Text] [Related]  

  • 19. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.
    Masi G; Vasile E; Loupakis F; Cupini S; Fornaro L; Baldi G; Salvatore L; Cremolini C; Stasi I; Brunetti I; Fabbri MA; Puglisi M; Trenta P; Granetto C; Chiara S; Fioretto L; Allegrini G; Crinò L; Andreuccetti M; Falcone A
    J Natl Cancer Inst; 2011 Jan; 103(1):21-30. PubMed ID: 21123833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The feasibility of a short bevacizumab infusion in patients with metastatic colorectal cancer.
    Terazawa T; Nishitani H; Kato K; Hashimoto H; Akiyoshi K; Iwasa S; Nakajima TE; Hamaguchi T; Yamada Y; Shimada Y
    Anticancer Res; 2014 Feb; 34(2):1053-6. PubMed ID: 24511054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.